Plant-produced hepatitis B core protein chimera carrying anthrax protective antigen domain-4

Hybridoma
Katarzyna BandurskaMaxim Golovkin

Abstract

The hepatitis B core antigen (HBcAg) can generate a strong immune response and is recognized as an effective carrier for foreign epitopes. The domain-4 epitope of the anthrax protective antigen (PA-D4) plays an essential role in generating protective immunity against virulent Bacillus anthracis. Here we report the successful production of a recombinant protein comprised of the antigenic PA-D4 integrated into the c/e1 loop of HBcAg in transgenic low-alkaloid Nicotiana tabacum. Sera of mice injected with the plant-derived purified HB/PA-D4 protein exhibited significant anti-PA- and anti-HBcAg-specific IgG titers; however, formation of virus-like particles (VLP) was not observed. These data support the feasibility of producing complex protein chimeras in plants.

References

Apr 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·R B HorschR T Fraley
Jan 1, 1995·Intervirology·M Seifer, D N Standring
Mar 3, 1999·Proceedings of the National Academy of Sciences of the United States of America·P A KratzM Nassal
Aug 18, 2001·Intervirology·P Pumpens, E Grens
Dec 1, 2001·Expert Opinion on Biological Therapy·J T Schiller, D R Lowy
Jan 1, 2003·Biochemical and Biophysical Research Communications·Y LobainaJ C Aguilar
Jul 10, 2004·Nature·Eugenio SantelliRobert C Liddington
Mar 1, 2005·Vaccine·Hilary Koprowski
Jun 7, 2005·Advanced Drug Delivery Reviews·Robert N Brey
Jun 16, 2005·Proceedings of the National Academy of Sciences of the United States of America·Natalia PogrebnyakHilary Koprowski
Aug 23, 2005·Journal of Virological Methods·I A MechtcheriakovaG P Lomonossoff
Oct 21, 2005·Biochemical and Biophysical Research Communications·R BrodzikH Koprowski
Nov 18, 2005·Trends in Plant Science·Julian K-C MaRichard M Twyman
Jul 4, 2006·Trends in Biotechnology·Stephen J Streatfield
Sep 26, 2006·Methods : a Companion to Methods in Enzymology·Luca SantiHugh Mason
Oct 13, 2006·Nature Biotechnology·Jeffrey L Fox
Jan 9, 2007·Plant Biotechnology Journal·Stephen J Streatfield
Feb 7, 2007·Vaccine·Jessica A ChichesterVidadi Yusibov
Mar 21, 2007·Current Opinion in Biotechnology·Yuri GlebaSylvestre Marillonnet
Apr 13, 2007·Proceedings of the National Academy of Sciences of the United States of America·Maxim GolovkinHilary Koprowski
Sep 14, 2007·BMC Biotechnology·Thomas O KohlEdward P Rybicki

❮ Previous
Next ❯

Citations

Apr 21, 2011·Plant Cell Reports·Ruth Elena Soria-GuerraSergio Rosales-Mendoza
Jan 6, 2012·Plant Cell Reports·Chiara LicoLinda Avesani
Jun 18, 2014·Monoclonal Antibodies in Immunodiagnosis and Immunotherapy·Kisung Ko
Sep 22, 2015·Plant Biotechnology Journal·Stephen J StreatfieldVidadi Yusibov
Sep 8, 2016·Expert Review of Vaccines·Verónica A Márquez-EscobarOmar González-Ortega
Jan 1, 2019·Biotechnology and Bioengineering·Hayley K Charlton HumeLinda H L Lua

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Anthrax Vaccines (ASM)

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.